Palma Sabatowa? Co to daje?

Biniu co na zakola? Slyszalem ze palma sabatowa daje rewelacyjne wyniki? Co otym sadzicie?

kanarek- dlaczego nie polecasz saw palmetto w okresie dojrzewania? Przecież to tylko zieleninka;)...

Saw Palmetto hamuje konwersje DHT wiec powinna pomoc
I stosuje ja wielu ludzi - wie mozesz sprobowac - jednak nie znam sie dokladniena tym temacie wiec tylko tyle niestety moge powiedziec
pozdrawiam

Wiedza to podstawa
"Madry człowiek powinien wiedzieć, że zdrowie jest jego najcenniejszą własnością i powinien uczyć się, jak sam może leczyć swoje choroby".
HIPOKRATES
Doradca w dziale Alternatywna Droga.

dzieki za info:) Tylko gdzie to mozna dostac?

eee
o czym mowa ?
bo nic nie lapie z tej chinszczyzny ?

"Zmartwienie rodzi się z czasu, który upływa, a nie wydaje owocu."

o Saw Palmetto
a dostac mozna w postaci suplementow np w sklepach z odzywkami
pozdrawiam i lece na dzisij wiec narazie.

Wiedza to podstawa
"Madry człowiek powinien wiedzieć, że zdrowie jest jego najcenniejszą własnością i powinien uczyć się, jak sam może leczyć swoje choroby".
HIPOKRATES
Doradca w dziale Alternatywna Droga.

Saw Palmetto znajduje sie w Fitoproscie - preparacie dostepnym na naszym ryku - jednak jesli jestes w okresie dojrzewania jeszce (nie dziw sie ze mowie o tym bo mam znajomego ktory ma 20 lat i jest juz prawie lysy) to odradzam. Jesli po okresie - zainteresuj sie Fitoprostem
pozdrawiam

Wiedza to podstawa
"Madry człowiek powinien wiedzieć, że zdrowie jest jego najcenniejszą własnością i powinien uczyć się, jak sam może leczyć swoje choroby".
HIPOKRATES
Doradca w dziale Alternatywna Droga.

kanarek, ten fitoprost jest na recepte? znasz moze dawke palmy w fitoproscie? mam 23 lata wiec jestem raczej po okresie dojz.
A wogule ma ktos jakies badania dot skutecznosci palmy ?
Mile widziane doswiadczenia wlasne np. forumowiczów.
I czy sa jakies ogolne zalecenia co do dawek jakie sie bierze wlasnie na lysienie a nie na " juniora" ?

Cos sie znajdzie:
Fitoprost jest bez recepty
Przed chwila znajomy kupowal - zaplacil 28zl dokladnie.Dawka jest standardowa - 160mg - kapsulek w Fitoproscie jest 60 a dawkuje sie ja 2x/dzien jesli dobrze pamietam wiec starcza opakowanie na miesieczna kuracje.
Ludzie stusujacy go z tego co wiem widzieli poprawe - stosujac na lysienie.
Stsuje sie (sparwdze dokaldnie bona szybko pisze) pol roku po czym nastepuje 3 miesieczna przerwa.

Badania sa - wkleje jutro jak znajde dokladnie cos konkretnego.
pozdrawiam

poszukam tez opinii uzytkownikow




Wiedza to podstawa
"Madry człowiek powinien wiedzieć, że zdrowie jest jego najcenniejszą własnością i powinien uczyć się, jak sam może leczyć swoje choroby".
HIPOKRATES
Doradca w dziale Alternatywna Droga.

First off saw palmetto is a 5-alpha reductase inhibitor (5-AR is responsible for reducing test to DHT), it has no 'blocking effect' at the androgen receptor to my knowledge. In an off-cycle situation, inhibiting 5-AR (depends on what type and how much) will decrease DHT and will increase endogenous test production and therefore estrogens as well (via aromatization). Because DHT is an aromatase inhibitor (and for other reasons) the natural test:estrogens ratio gets skewed (which can cause gyno problems btw, although this is rare from saw palmetto, and is more often noticed with proscar).


DHT is 8-10 times more potent than testosterone in promoting prostate growth, and suppressing DHT is a proven therapy in treating benign prostate enlargement.
Saw palmetto extract mildly lowers DHT in the prostate gland, it also inhibits estrogen binding to the prostate. Saw Palmetto extract also
is antagonistic to the enzyme 3-ketosteroid which is responsible for the binding of DHT to the prostate gland.


Saw Palmetto has been shown to do just about everything. It also blocks the alpha 1 adrenoreceptor (in vitro), another possible mechanism whereby it could shrink the prostate as well as improve urinary symptoms by relaxing the bladder (1).


Drugs Aging. 1996 Nov;9(5):379-95.

Serenoa repens (Permixon). A review of its pharmacology and therapeutic efficacy in benign prostatic hyperplasia.

Plosker GL, Brogden RN.

Adis International Limited, Auckland, New Zealand.

Serenoa repens (Permixon) has been available for several years for the treatment of men with benign prostatic hyperplasia (BPH). The drug is the n-hexane lipidosterolic extract of the dwarf American palm (also known as Serenoa repens) and is a complex mixture of various compounds. A number of pharmacodynamic effects have been demonstrated with the lipidosterolic extract of Serenoa repens (LSESR), suggesting multiple mechanisms of action including in vitro inhibition of both type 1 and type 2 isoenzymes of 5 alpha-reductase and interference with binding of dihydrotestosterone to cytosolic androgen receptors in prostate cells. In controlled clinical trials in men with BPH, oral administration of Serenoa repens 160 mg twice daily for 1 to 3 months was generally superior to placebo in improving subjective symptoms, such as dysuria, as well as objective parameters. The frequency of nocturia was reduced by 33 to 74%, while urinary frequency during the day decreased by 11 to 43% and peak urinary flow rate increased by 26 to 50% with Serenoa repens. Corresponding values for placebo were 13 to 39%, 1 to 29% and 2 to 35%. The only large comparative trial conducted to date, in which > 1000 men with moderate BPH were randomised to receive Serenoa repens 160 mg twice daily or finasteride 5 mg once daily for 6 months, demonstrated similar efficacy between the two drugs. No statistically significant difference was demonstrated between treatment groups for improvement in patient self-rated quality-of-life scores and the primary end-point of objective symptom score; International Prostate Symptom Score improved by 37% with Serenoa repens compared with 39% with finasteride. In much smaller comparative trials, few significant differences were demonstrated between Serenoa repens and alpha 1-receptor antagonists, and larger randomised trials of adequate duration are required to better compare the clinical efficacy of these drugs. The most frequently reported adverse events in clinical trials with Serenoa repens have been minor gastrointestinal problems (e.g. nausea and abdominal pain). In conclusion, Serenoa repens is well tolerated and has greater efficacy than placebo and similar efficacy to finasteride in improving symptoms in men with BPH. Although there is a need for further comparative studies, particularly with alpha 2-receptor antagonists, available data indicate that Serenoa repens is a useful alternative to alpha 1-receptor antagonists and finasteride in the treatment of men with BPH.

(1) Prostate. 1999 Feb 15;38(3):208-15.

Saw palmetto extracts potently and noncompetitively inhibit human alpha1-adrenoceptors in vitro.

Goepel M, Hecker U, Krege S, Rubben H, Michel MC.


Saw Palmetto seems to be prostate selective when it comes to 5 alpha reductase inhibition (1). However, it binds to the androgen receptor in fibrobasts as well as prostate cells (2). As you recall, fibroblasts give rise to connective tissue but not skeletal muscle, so we still don't know the effects in muscle. Nevertheless, if a person wanted to use a 5 alpha reductase inhibitor to treat BHP, it might be prudent to use finasteride or dutasteride instead of Saw Palmetto.


It might help prevent male pattern baldness if it antagonizes the AR in the scalp, even if it has no effect on DHT production. But that's not really what you want to hear because that is just more ammo for the possibility that it blocks the AR everywhere.



Serenoa repens for benign prostatic hyperplasia.
Wilt T, Ishani A, Mac Donald R.
General Internal Medicine (111-0), Minneapolis VA/VISN 13 Center for Chronic Disease Outcomes Research, One Veterans Drive, Minneapolis, Minnesota 55417, USA. [email protected]

BACKGROUND: Benign prostatic hyperplasia (BPH), nonmalignant enlargement of the prostate, can lead to obstructive and irritative lower urinary tract symptoms (LUTS). The pharmacologic use of plants and herbs (phytotherapy) for the treatment of LUTS associated with BPH has been growing steadily. The extract of the American saw palmetto or dwarf palm plant, Serenoa repens (also known by its botanical name of Sabal serrulatum), is one of the several phytotherapeutic agents available for the treatment of BPH. OBJECTIVES: This systematic review aimed to assess the effects of Serenoa repens in the treatment of LUTS consistent with BPH. SEARCH STRATEGY: Trials were searched in computerized general and specialized databases (MEDLINE, EMBASE, Cochrane Library, Phytodok), by checking bibliographies, and by contacting manufacturers and researchers. SELECTION CRITERIA: Trials were eligible if they (1) randomized men with BPH to receive preparations of Serenoa repens (alone or in combination) in comparison with placebo or other BPH medications, and (2) included clinical outcomes such as urologic symptom scales, symptoms, or urodynamic measurements. Eligibility was assessed by at least two independent observers. DATA COLLECTION AND ANALYSIS: Information on patients, interventions, and outcomes was extracted by at least two independent reviewers using a standard form. The main outcome measure for comparing the effectiveness of Serenoa repens with placebo or other BPH medications was the change in urologic symptom scale scores. Secondary outcomes included changes in nocturia and urodynamic measures. The main outcome measure for side effects was the number of men reporting side effects. MAIN RESULTS: In this update, 3 new trials involving 230 additional men (7.8%) have been included. 3139 men from 21 randomized trials lasting 4 to 48 weeks were assessed. 18 trials were double-blinded and treatment allocation concealment was adequate in 11 studies. Compared with placebo, Serenoa repens improved urinary symptom scores, symptoms, and flow measures. The weighted mean difference (WMD) for the urinary symptom score was -1.41 points (scale range 0-19), (95%CI = -2.52, -0.30, n = 1 study) and the risk ratio (RR) for self rated improvement was 1.76 (95%CI = 1.21, 2.54, n = 6 studies). The WMD for nocturia was -0.76 times per evening (95%CI = -1.22, -0.32; n = 10 studies). The WMD for peak urine flow was 1.86 ml/sec (95%CI = 0.60, 3.12, n = 9 studies). Compared with finasteride, Serenoa repens produced similar improvements in urinary symptom scores (WMD = 0.37 IPSS points (scale range 0-35), 95%CI = -0.45, 1.19, n = 2 studies) and peak urine flow (WMD = -0.74 ml/sec, 95%CI = -1.66, 0.18, n = 2 studies). Adverse effects due to Serenoa repens were mild and infrequent. Withdrawal rates in men assigned to placebo, Serenoa repens or finasteride were 7%, 9%, and 11%, respectively. REVIEWER'S CONCLUSIONS: The evidence suggests that Serenoa repens provides mild to moderate improvement in urinary symptoms and flow measures. Serenoa repens produced similar improvement in urinary symptoms and flow compared to finasteride and is associated with fewer adverse treatment events. The long term effectiveness, safety and ability to prevent BPH complications are not known. The results of this update are in agreement with our initial review.
...

As for MPB, here is one study that seems to show Saw Palmetto to be effective.

...
A randomized, double-blind, placebo-controlled trial to determine the effectiveness of botanically derived inhibitors of 5-alpha-reductase in the treatment of androgenetic alopecia.
Prager N, Bickett K, French N, Marcovici G.
Clinical Research and Development Network, Aurora, CO, USA.

BACKGROUND: Androgenetic alopecia (AGA) is characterized by the structural miniaturization of androgen-sensitive hair follicles in susceptible individuals and is anatomically defined within a given pattern of the scalp. Biochemically, one contributing factor of this disorder is the conversion of testosterone (T) to dihydrotestosterone (DHT) via the enzyme 5-alpha reductase (5AR). This metabolism is also key to the onset and progression of benign prostatic hyperplasia (BPH). Furthermore, AGA has also been shown to be responsive to drugs and agents used to treat BPH. Of note, certain botanical compounds have previously demonstrated efficacy against BPH. Here, we report the first example of a placebo-controlled, double-blind study undertaken in order to examine the benefit of these botanical substances in the treatment of AGA. OBJECTIVES: The goal of this study was to test botanically derived 5AR inhibitors, specifically the liposterolic extract of Serenoa repens (LSESr) and beta-sitosterol, in the treatment of AGA. Subjects: Included in this study were males between the ages of 23 and 64 years of age, in good health, with mild to moderate AGA. RESULTS: The results of this pilot study showed a highly positive response to treatment. The blinded investigative staff assessment report showed that 60% of (6/10) study subjects dosed with the active study formulation were rated as improved at the final visit. CONCLUSIONS: This study establishes the effectiveness of naturally occurring 5AR inhibitors against AGA for the first time, and justifies the expansion to larger trials.
...

Saw palmetto alters nuclear measurements reflecting DNA content in men with symptomatic BPH: evidence for a possible molecular mechanism.
Veltri RW, Marks LS, Miller MC, Bales WD, Fan J, Macairan ML, Epstein JI, Partin AW.
Department of Urology, Johns Hopkins Medical Institutions, Baltimore, Maryland, USA.

OBJECTIVES: To examine the nuclear chromatin characteristics of epithelial cells, looking for an SPHB-mediated effect on nuclear DNA structure and organization. Saw palmetto herbal blend (SPHB) causes contraction of prostate epithelial cells and suppression of tissue dihydrotestosterone levels in men with symptomatic benign prostatic hyperplasia, but a fundamental mechanism remains unknown. METHODS: A 6-month randomized trial, comparing prostatic tissue of men treated with SPHB (n = 20) or placebo (n = 20), was performed. At baseline, the two groups were similar in age (65 versus 64 years), symptoms (International Prostate Symptom Score 18 versus 17), uroflow (maximal urinary flow rate 10 versus 11 mL/s), prostate volume (59 versus 58 cm(3)), prostate-specific antigen (4.2 versus 2.7 ng/mL), and percentage of epithelium (17% versus 16%). Prostatic tissue was obtained by sextant biopsy before and after treatment. Five-micron sections were Feulgen stained and quantitatively analyzed using the AutoCyte QUIC-DNA imaging system. Images were captured from 200 randomly selected epithelial cell nuclei, and 60 nuclear morphometric descriptors (NMDs) (eg, size, shape, DNA content, and textural features) were determined for each nucleus. Logistic regression analysis was used to assess the differences in the variances of the NMDs between the treated and untreated prostate epithelial cells. RESULTS: At baseline, the SPHB and placebo groups had similar NMD values. After 6 months of placebo, no significant change from baseline was found in the NMDs. However, after 6 months of SPHB, 25 of the 60 NMDs were significantly different compared with baseline, and a multivariate model for predicting treatment effect using 4 of the 25 was created (P <0.001). The multivariate model had an area under the receiver operating characteristic curve of 94% and an accuracy of 85%. CONCLUSIONS: Six months of SPHB treatment appears to alter the DNA chromatin structure and organization in prostate epithelial cells. Thus, a possible molecular basis for tissue changes and therapeutic effect of the compound is suggested.
...

Your body is smarter than you !
Your body hates you !
Alternatywna Droga'-2003
konsultant-mafii.suple.hardcor.pl

dzieki wielkie dla Kanarka i Binia za arty:) A teraz idem sie doksztalcac w angielskim ale to juz off line bo niestety stukam z modemu:(. Thx i spokojnej nocki.

Do kanarka( ale do innych tez:) )
Czy w fito jest nap. palma?
z lysienie kropka com jest co prawda link do fitoprostu ale...
na ulotce( dzis kupilem) pisze ze skald to : SERENOAE REPENS FRUCTUS EXTRACTUM
nie znam laciny:) to napewno jest palma sabatowa?
Glupio byloby brac cos rok nie wiedzac cio to jest:)